BLOOD TEST MAY DETERMINE LEVEL OF MULTIPLE SCLEROSIS IN PATIENTS

An Ottawa doctor has found that a blood test may predict the activity of multiple sclerosis. Dr. Mark Freedman, a University of Ottawa professor and neurologist at the Ottawa Hospital, discovered that a test successfully determined whether patients would develop an active form of the disease after their first neurological attack, according to a press release. Results are based on a small sample of patients, but point to the possibility that the blood test could allow neurologists to prescribe proper treatment early on. Doctors now cannot predict whether a patient who has suffered a single neurological event — such as a lengthy onset of double vision, numbness from the waist down, or sudden unsteadiness when walking — will develop a mild or active form of MS. The uncertainty can cause people who do not require treatment for an active form to receive expensive therapy that can lead to adverse side effects or anxiety. Conversely, others who will face the active form might not receive initial aggressive treatment. “Knowing at this earliest time point that a patient is destined to develop active disease would greatly assist this decision,” Dr. Freedman is quoted as saying in the statement. Dr. William McIlroy, national medical advisor with the MS Society of Canada, cautioned that the sample size was small, but called the findings “potentially ... an exciting, important development. If you see a person who’s only had one attack right now, you just don’t know whether their disease is going to progress rapidly over the next couple of years or whether it’s going to progress more slowly,” Dr. McIlroy said in an interview. “Do you want to subject people to costs and uncertainties and injections if it’s not necessary at this time?” Dr. McIlroy said the current trend is to treat MS patients early rather than late because the benefit appears to be greatest with early treatment. The test, which uses certain markers in the blood, is developed by Glycominds Ltd., an Israel-based company. Using retrospective blood samples taken from 90 patients after their first neurological attack, it correctly identified the 36% of patients who suffered additional events in a two- year period after the first attacks, according to the release. Dr. Freedman is to discuss the findings at the joint meeting of the European and Americas committees for the treatment and research in Multiple Sclerosis, taking place this week in Thessaloniki, Greece.